
ZURA Stock Forecast & Price Target
ZURA Analyst Ratings
Bulls say
Zura Bio is a clinical-stage biotechnology company with a diverse pipeline of novel treatments for autoimmune and inflammatory diseases, including those with significant unmet needs. With a focus on complex and chronic conditions, Zura Bio is developing innovative therapies that have the potential to improve treatment outcomes for a broad range of patients. With recent positive data readouts and ongoing development in key indications, the company is well-positioned for continued success and growth in the future.
Bears say
Zura Bio is facing significant risks to the attainment of its price target and rating due to potential clinical and regulatory failures of its lead programs, logistical challenges in drug manufacturing and shipment, and potential commercial challenges from current and future therapies. These risks are further compounded by the high expectations for the NEXUS-PMR study, which will begin in the next few years and will need to show significant efficacy and safety to meet its primary and secondary endpoints. Additionally, the trial's power for a delta of around 25% on the primary endpoint indicates the potential for disappointment if the results fall short of expectations.
This aggregate rating is based on analysts' research of Zura Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.
ZURA Analyst Forecast & Price Prediction
Start investing in ZURA
Order type
Buy in
Order amount
Est. shares
0 shares